Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.365 USD | -14.75% | +31.87% | -54.63% |
May. 10 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
May. 10 | Sector Update: Health Care | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 532.7 | 1,285 | 983.2 | 412.5 | 596.7 | 273.4 | - | - |
Enterprise Value (EV) 1 | 316.9 | 1,104 | 983.2 | 412.5 | 366.9 | 209.4 | 273.4 | 273.4 |
P/E ratio | -3.44 x | -9.26 x | -4.76 x | -3.44 x | -64.1 x | -1.48 x | -2.42 x | -2.16 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 8.3 x | 12.3 x | 12.7 x | 2.71 x | 10.2 x | 3.97 x | 2.52 x | 2.43 x |
EV / Revenue | 4.94 x | 10.5 x | 12.7 x | 2.71 x | 6.25 x | 3.04 x | 2.52 x | 2.43 x |
EV / EBITDA | -1.91 x | -9.25 x | -5.13 x | -3.77 x | -2.31 x | -1.17 x | -3 x | -1.69 x |
EV / FCF | -2.24 x | -9.37 x | -6.55 x | -4.55 x | -4.59 x | -1.16 x | -1.39 x | -1.32 x |
FCF Yield | -44.6% | -10.7% | -15.3% | -22% | -21.8% | -86.1% | -72.2% | -75.8% |
Price to Book | 2.31 x | 4.05 x | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 48,958 | 56,204 | 61,258 | 61,475 | 62,029 | 62,633 | - | - |
Reference price 2 | 10.88 | 22.86 | 16.05 | 6.710 | 9.620 | 4.365 | 4.365 | 4.365 |
Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 64.19 | 104.9 | 77.45 | 151.9 | 58.75 | 68.93 | 108.7 | 112.3 |
EBITDA 1 | -166.3 | -119.4 | -191.5 | -109.6 | -158.6 | -179.5 | -91.07 | -161.8 |
EBIT 1 | -177.2 | -131.1 | -202.8 | -121.4 | -168.2 | -183.4 | -169.6 | -188.7 |
Operating Margin | -276.04% | -124.96% | -261.85% | -79.91% | -286.38% | -266.07% | -156.01% | -167.93% |
Earnings before Tax (EBT) 1 | -151.8 | -129.7 | -202.1 | -119.8 | -9.058 | -180.1 | -159.7 | -180.9 |
Net income 1 | -151.8 | -129.7 | -202.1 | -119.8 | -9.058 | -181.5 | -124.2 | -164.6 |
Net margin | -236.51% | -123.7% | -260.97% | -78.82% | -15.42% | -263.26% | -114.28% | -146.48% |
EPS 2 | -3.160 | -2.470 | -3.370 | -1.950 | -0.1500 | -2.951 | -1.800 | -2.024 |
Free Cash Flow 1 | -141.4 | -117.8 | -150 | -90.58 | -79.97 | -180.2 | -197.3 | -207.2 |
FCF margin | -220.35% | -112.32% | -193.72% | -59.62% | -136.12% | -261.47% | -181.5% | -184.47% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 14.15 | 11.1 | 26.01 | 41.73 | 73.1 | 24.5 | 13.14 | 10.4 | 10.72 | 9.104 | 18.27 | 14.79 | 22.89 | 12.5 | 12.5 |
EBITDA 1 | - | - | - | - | - | - | - | - | -47.45 | -51.91 | -45.79 | -44.11 | -42.08 | - | - |
EBIT 1 | -58.24 | -66.64 | -41.81 | -24.96 | 11.98 | -38.43 | -44.96 | -35.5 | -49.35 | -53.75 | -43.65 | -48.45 | -41.96 | -58.6 | -58.6 |
Operating Margin | -411.65% | -600.29% | -160.76% | -59.8% | 16.39% | -156.87% | -342.28% | -341.46% | -460.39% | -590.4% | -238.9% | -327.55% | -183.29% | -468.8% | -468.8% |
Earnings before Tax (EBT) 1 | -58.02 | -66.44 | -41.3 | -24.81 | 12.8 | -38.01 | 57.47 | 17.55 | -46.07 | -52.19 | -42.63 | -47.91 | -40.14 | -58.6 | -58.6 |
Net income 1 | -58.02 | -66.44 | -41.3 | -24.81 | 12.8 | -38.01 | 57.47 | 17.55 | -46.07 | -52.19 | -43.01 | -47.64 | -40.99 | -58.6 | -58.6 |
Net margin | -410.14% | -598.53% | -158.82% | -59.46% | 17.51% | -155.16% | 437.49% | 168.84% | -429.78% | -573.26% | -235.44% | -322.02% | -179.08% | -468.8% | -468.8% |
EPS 2 | -0.9500 | -1.080 | -0.6700 | -0.4000 | 0.2100 | -0.6100 | 0.9200 | 0.2800 | -0.7500 | -0.8400 | -0.7086 | -0.7655 | -0.6660 | -0.9000 | -0.9000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/24/22 | 5/3/22 | 8/8/22 | 11/3/22 | 3/15/23 | 5/9/23 | 8/9/23 | 11/6/23 | 3/7/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 216 | 181 | - | - | 230 | 64 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -141 | -118 | -150 | -90.6 | -80 | -180 | -197 | -207 |
ROE (net income / shareholders' equity) | -64.1% | -49.3% | -75.5% | -62.8% | -6.15% | -259% | -137% | -63% |
ROA (Net income/ Total Assets) | -47.1% | - | - | - | - | - | - | - |
Assets 1 | 322.3 | - | - | - | - | - | - | - |
Book Value Per Share | 4.710 | 5.640 | - | - | - | - | - | - |
Cash Flow per Share | - | -2.130 | - | - | - | - | - | - |
Capex 1 | 4.29 | 5.91 | 6.2 | 3.62 | 1.76 | 3.32 | 1.91 | 1.54 |
Capex / Sales | 6.68% | 5.63% | 8.01% | 2.38% | 3% | 4.82% | 1.76% | 1.37% |
Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.63% | 321M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- MGNX Stock
- Financials MacroGenics, Inc.